MedPath

Cyclarity Therapeutics, Inc.

Cyclarity Therapeutics, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2019-11-01
Employees
1
Market Cap
-
Website
http://www.cyclaritytx.com

Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Patients

Early Phase 1
Recruiting
Conditions
Atherosclerotic Cardiovascular Disease
Acute Coronary Syndromes
Interventions
Other: Placebo
First Posted Date
2025-02-06
Last Posted Date
2025-05-02
Lead Sponsor
Cyclarity Therapeutics, Inc.
Target Recruit Count
84
Registration Number
NCT06813339
Locations
🇦🇺

CMAX Clinical Research, Adelaide, South Australia, Australia

© Copyright 2025. All Rights Reserved by MedPath